Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical and biotechnology company focused on developing effective, rapid-acting and convenient mental health treatments. The AtaiBeckley news feed on Stock Titan aggregates company announcements, press releases and regulatory disclosures so readers can follow how its clinical programs and corporate developments evolve over time.
News about AtaiBeckley frequently highlights progress across its pipeline of investigational therapies. This includes updates on BPL-003, a mebufotenin (5-MeO-DMT) benzoate nasal spray for treatment-resistant depression and alcohol use disorder; VLS-01, a DMT buccal film for treatment-resistant depression; and EMP-01, an oral R-MDMA formulation for social anxiety disorder. Company releases have covered Phase 2b and open-label extension data for BPL-003, enrollment and site expansion for VLS-01 trials, and exploratory Phase 2a work for EMP-01, as well as regulatory milestones such as FDA Breakthrough Therapy designation for BPL-003.
Investors and observers can also use the ATAI news page to follow corporate events, including the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited to form AtaiBeckley, the company’s redomiciliation to the United States as AtaiBeckley Inc., and its addition to the Nasdaq Biotechnology Index. Filings and press releases related to public offerings, grants from organizations such as the National Institute on Drug Abuse, and intellectual property developments like the U.S. patent granted for EMP-01 are also reflected in the news flow.
By reviewing AtaiBeckley news in one place, readers can track key clinical milestones, financing activities, regulatory designations and strategic transactions that shape the company’s efforts in mental health therapeutics. The ATAI news page can be revisited regularly to see new company communications and related market updates as they are released.
AtaiBeckley (NASDAQ: ATAI) was added to the S&P Total Market Index, S&P Completion Index and CRSP U.S. benchmark indices, effective March 23, 2026. Inclusion in CRSP triggers mandatory position-building by passive index funds tracking more than $3 trillion in assets.
The company said its BPL-003 Phase 3 program remains on track to initiate in Q2 2026, with topline VLS-01 Phase 2b data expected in H2 2026. These additions follow inclusion in the Nasdaq Biotechnology Index in December 2025.
AtaiBeckley (NASDAQ: ATAI) reported peer-reviewed Phase 2a Cohort 1 results for BPL-003 in treatment-resistant depression (TRD). A single 10 mg intranasal dose produced a mean MADRS reduction of 12.6 points by Day 2 (27.5 to 14.8), sustained to Day 85 (14.5).
Response rate ≥50% was 54.5% through Day 85; 63.6% achieved remission at one or more timepoints. SHAPS improved from 8.4 to 1.5. No serious adverse events or withdrawals were reported. Phase 3 remains on track to initiate in Q2 2026 after a successful EOP2 meeting.
AtaiBeckley (NASDAQ: ATAI) said it remains on track to start two parallel Phase 3 studies of BPL-003 in Q2 2026 after a successful End-of-Phase 2 meeting with the FDA. BPL-003 holds Breakthrough Therapy Designation and showed rapid Day 2 antidepressant effects and durable improvements through eight weeks in Phase 2b.
The company reaffirmed cash runway into early 2029, outlined a scalable commercial model aligned with interventional psychiatry workflows, noted positive Phase 2a results for EMP-01, and expects VLS-01 Phase 2 topline in H2 2026.
AtaiBeckley (NASDAQ: ATAI) reported Q4 and full-year 2025 results and clinical updates on March 6, 2026. Key clinical milestones include a successful FDA End-of-Phase 2 meeting for BPL-003 and Phase 3 initiation targeted for Q2 2026, VLS-01 Phase 2 topline readout expected in H2 2026, and positive Phase 2a EMP-01 SAD results. Financially, cash and short-term securities totaled $220.7M at year-end and management expects runway into early 2029. The company completed a strategic combination and U.S. redomiciliation in late 2025.
AtaiBeckley (NASDAQ: ATAI) announced a successful End-of-Phase 2 meeting with the FDA for BPL-003, its intranasal mebufotenin benzoate for treatment-resistant depression. The FDA indicated support for a dual pivotal Phase 3 program and provided feedback on the safety database.
The company expects Phase 3 initiation on track for Q2 2026, notes BPL-003 has Breakthrough Therapy designation (Oct 2025), and will host a Virtual Investor Day on March 6, 2026 to detail the Phase 3 strategy.
AtaiBeckley (NASDAQ: ATAI) reported positive topline results from a Phase 2a trial of EMP-01 (oral R-MDMA) in adults with Social Anxiety Disorder on February 26, 2026. The study met its primary safety objective with no serious adverse events and high retention.
EMP-01 showed a placebo-adjusted LSAS reduction of 11.85 points at Day 43 (Hedges’ g=0.45; p=0.036 one-tailed), 49% CGI‑I responders vs. 15% placebo (NNT 2.95). Seventy-one patients enrolled across seven UK sites; detailed analyses will appear at scientific venues.
AtaiBeckley (NASDAQ: ATAI) will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will include presentations and live Q&A with the company’s executive leadership and external key opinion leaders.
Investors, analysts, and media may register for the live webcast; a replay will be posted afterward on the company’s investor website under Events.
AtaiBeckley (NASDAQ: ATAI) appointed Michael Faerm as Chief Financial Officer effective March 9, 2026. Faerm brings more than 25 years of finance, equity research and banking experience and will lead financial strategy, capital markets and operations. Anne Johnson will transition to Chief Accounting Officer to preserve continuity. The company noted BPL-003 is advancing toward Phase 3 as its clinical programs progress.
AtaiBeckley (NASDAQ: ATAI) said its CEO Srinivas Rao, M.D., Ph.D., and VP of Investor Relations Jason Awe, Ph.D., will attend investor conferences in March 2026 with fireside chats and one-on-one meetings.
Events: TD Cowen (Boston) on March 4 with a fireside chat 11:50am–12:20pm EST; Jefferies Biotech on March 10 (one-on-ones) in Miami; Leerink (Miami) on March 11 with a fireside chat 8:00am–8:30am EST. Live webcasts of the fireside chats will be available on the company's investor site and archived for at least 30 days.
AtaiBeckley (NASDAQ: ATAI) presented new clinical and preclinical data at the 64th Annual ACNP Meeting (Jan 12–15, 2026) in Nassau, Bahamas. A Phase 2b double-blind study of intranasal BPL-003 (mebufotenin benzoate) showed that a single 8 mg or 12 mg dose produced a significant, rapid, and sustained antidepressant effect versus a 0.3 mg sub-perceptual control at all timepoints, with both active doses reported as well-tolerated. The BPL-003 poster was selected for the Hot Topics Session. A separate preclinical poster on 5-MeO-DMT reported pharmacology, pharmacokinetics, and potential neuroplasticity-relevant effects supporting further investigation. The company said these results support moving toward Phase 3 evaluation for BPL-003.